Intellia Therapeutics to Host Educational Briefing Webinar on Interference Proceedings Relating to CRISPR/Cas9 Genome Editing...
23 August 2018 - 10:30PM
Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing
company focused on developing curative therapeutics using
CRISPR/Cas9 technology, will host an educational briefing session
for investors addressing the interference proceedings between The
University of California, University of Vienna, and Emmanuelle
Charpentier and the Broad Institute/Massachusetts Institute of
Technology/Harvard University relating to the CRISPR/Cas9 genome
editing technology patents, in advance of the U.S. Court of Appeals
for the Federal Circuit’s decision.
The educational webinar will take place on Tue.,
Aug. 28, 2018 at 8 a.m. ET. Investors are invited to join the
webinar led by Cora Holt, Finnegan, Henderson, Farabow, Garrett
& Dunner, LLP. The webinar will be followed by a
question-and-answer session.
To participate in the webinar and Q&A session, please visit
this link, or the “Upcoming Events” section of Intellia’s website
at intelliatx.com, at 8 a.m. on Tuesday.
About Intellia Therapeutics
Intellia Therapeutics is a leading genome editing company
focused on developing proprietary, curative therapeutics using the
CRISPR/Cas9 system. Intellia believes the CRISPR/Cas9 technology
has the potential to transform medicine by permanently editing
disease-associated genes in the human body with a single treatment
course, and through improved cell therapies that can treat cancer
and immunological diseases by replacing patients’ diseased cells.
The combination of deep scientific, technical and clinical
development experience, along with its leading intellectual
property portfolio, puts Intellia in a unique position to unlock
broad therapeutic applications of the CRISPR/Cas9 technology and
create a new class of therapeutic products. Learn more about
Intellia Therapeutics and CRISPR/Cas9 at intelliatx.com and follow
us on Twitter @intelliatweets.
About Finnegan
Finnegan, Henderson, Farabow, Garrett & Dunner, LLP is one
of the largest IP law firms in the world. From offices in Atlanta,
Boston, London, Palo Alto, Reston, Seoul, Shanghai, Taipei, Tokyo,
and Washington, DC, the firm practices all aspects
of patent, trademark, copyright, and trade
secret law,
including counseling, prosecution, licensing,
and litigation. Finnegan also represents clients on IP issues
related to European patents and trade
marks, international trade, portfolio management,
the Internet, e-commerce, government
contracts, antitrust, and unfair competition. For
additional information on the firm, please
visit www.finnegan.com. Follow us
on LinkedIn and Twitter.
Investor
Contact:
Lindsey Trickett Vice President, Investor Relations +1 857-285-6211
lindsey.trickett@intelliatx.com
Media Contact:Jennifer Mound Smoter Senior Vice
President, External Affairs & Communications +1 857-706-1071
jenn.smoter@intelliatx.com
Intellia Therapeutics (NASDAQ:NTLA)
Historical Stock Chart
From Apr 2024 to May 2024
Intellia Therapeutics (NASDAQ:NTLA)
Historical Stock Chart
From May 2023 to May 2024